King's College London — Psychopharmacology & Cannabis Research
London, United KingdomFounded 2014
About King's College London — Psychopharmacology & Cannabis Research
King's College London conducts clinical research on CBD as a treatment for psychosis and anxiety, and studies the neurological effects of cannabis use on brain development.
Key Facts
- 1Conducted pivotal clinical trials showing CBD reduces psychotic symptoms, published in the American Journal of Psychiatry
- 2Uses fMRI brain imaging to map how THC and CBD affect neural circuits differently
Frequently Asked Questions
What did King's College discover about CBD and psychosis?
Their clinical trials demonstrated that CBD has antipsychotic properties and can reduce symptoms in patients with psychosis with minimal side effects.
Does the research support recreational cannabis?
The research is clinically focused; findings on THC's neurological effects are often cited in harm-reduction contexts rather than as endorsements.
More Cannabis Companies in London
Cannabis Laws
Products
- CBD clinical trial outcomes
- Neuroimaging study datasets
Specialties
CBD and psychosis researchCannabis neuroimaging studies
Company Details
- Location
- London, United Kingdom
- Founded
- 2014
- Publicly Traded
- No
Browse all Consulting & Education
View more companies in this category
Related Companies
More in United Kingdom
Zerenia Clinics
London \u2014 Medical & Pharma
Lyphe Group
London \u2014 Medical & Pharma
IPS Pharma
Leatherhead \u2014 Producer & Grower
GW Pharmaceuticals (Jazz Pharmaceuticals)
Cambridge \u2014 Medical & Pharma